8-K: NanoVibronix Announces 1-for-10 Reverse Stock Split

NanoVibronix, Inc. will effect a 1-for-10 reverse stock split of its common stock, effective August 11, 2025, to maintain Nasdaq listing.

Summary

• NanoVibronix, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split.
• The reverse stock split will become effective at 4:05 p.m. (Delaware time) on August 11, 2025.
• Every ten (10) shares of issued and outstanding common stock will be automatically combined into one (1) issued and outstanding share.
• No fractional shares will be issued; any fractional shares that would otherwise result from the split will be rounded up to the next whole number.
• The number of outstanding shares will be reduced from 7,968,868 shares to approximately 796,887 shares.
• The number of authorized shares of Common Stock will remain unchanged at 40,000,000 shares.
• Proportionate adjustments will be made to the per share exercise price and number of shares for outstanding equity awards under the 2024 and 2014 Long-Term Incentive Plans.
• The Common Stock will begin trading on a Reverse Stock Split-adjusted basis on the Nasdaq Capital Market on August 12, 2025, under the existing symbol NAOV.
• The new CUSIP number for the Common Stock following the Reverse Stock Split is 63008J884.

Sentiment

Score: 4

Explanation: While a reverse stock split is often a sign of a struggling stock price, it is a necessary step to maintain Nasdaq listing, which is crucial for liquidity and investor confidence. It does not fundamentally change the company's value but addresses a compliance issue. The company's continued focus on its medical technology platforms provides some underlying positive, but the immediate action is reactive to a low share price.

Positives

• Helps the company maintain its listing on the Nasdaq Capital Market, avoiding potential delisting due to low share price.
• May increase the per-share trading price, potentially attracting a broader range of investors or institutional interest.
• Simplifies the capital structure by reducing the number of outstanding shares.

Negatives

• Reverse stock splits are often viewed negatively by the market as they typically indicate a low stock price and underlying financial challenges.
• Does not fundamentally change the company's market capitalization or intrinsic value.
• May not prevent further stock price decline if underlying business issues persist.

Risks

• The effect that the reverse stock split may have on the price of the company's common stock.
• The company's ability to maintain its listing on the Nasdaq Capital Market.
• Market acceptance of the company's existing and new products or lengthy product delays in key markets.
• Negative or unreliable clinical trial results.
• Inability to secure regulatory approvals for the sale of the company's products.
• Intense competition in the medical device industry from much larger, multinational companies.
• Product liability claims and product malfunctions.
• The company's limited manufacturing capabilities and reliance on subcontractor assistance.
• Insufficient or inadequate reimbursements by governmental and/or other third-party payers for the company's products.
• The company's ability to successfully obtain and maintain intellectual property protection covering its products.
• Legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions.
• The company's reliance on single suppliers for certain product components.
• The need to raise additional capital to meet future business requirements and obligations, as such capital may not be available, or may be costly, dilutive, or difficult to obtain.
• Conducting business in foreign jurisdictions exposes the company to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions.
• General market and other conditions.

Future Outlook

The company aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation. Future platform expansion for ENvue may include pediatric and vascular access applications. The reverse stock split is intended to help maintain Nasdaq listing.

Management Comments

• NanoVibronix, Inc. announced its intention to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.
• NanoVibronix aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.

Industry Context

Reverse stock splits are a common corporate action for companies whose stock price has fallen below exchange minimums, such as Nasdaq's $1.00 bid price requirement. While they do not change a company's fundamental value, they are often a necessary step to maintain listing and avoid delisting, which can severely impact liquidity and investor confidence. This action aligns with similar moves by other small-cap companies in the medical technology sector facing market pressures or seeking to improve their stock's market perception.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism used by companies across various industries, including medical technology, to meet stock exchange listing requirements, such as Nasdaq's minimum bid price.
• For example, companies like Sorrento Therapeutics (SRNE) or Aeterna Zentaris (AEZS) have previously undertaken reverse stock splits to maintain Nasdaq compliance.
• The 1-for-10 ratio is within the typical range (often 1-for-2 to 1-for-50) approved by shareholders for such actions, similar to ratios seen in other small-cap biotech or med-tech firms.
• The rounding up of fractional shares is a common practice to simplify post-split shareholdings and avoid cash payments for small fractions.

Corporate Governance

Stakeholder Impact

• Shareholders: The number of shares held will decrease by a factor of ten, but the per-share price is expected to increase proportionally. Any fractional shares will be rounded up to the next whole number. Percentage ownership remains largely unchanged. This action helps maintain Nasdaq listing, which benefits liquidity and market access.

Next Steps

• Common stock begins trading on a split-adjusted basis on the Nasdaq Capital Market on August 12, 2025.
• Future platform expansion for ENvue may include pediatric and vascular access applications.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to maintain Nasdaq listing, which is a positive for the company's market presence and liquidity. However, it does not address the underlying reasons for the low stock price. Investors should hold to observe if the company can leverage its maintained listing to improve its operational performance and product adoption, especially with its medical technology platforms like PainShield, UroShield, and ENvue. A 'hold' recommendation allows for observation of post-split trading behavior and future business developments without immediate divestment or further investment based solely on this corporate action.

Keywords

NanoVibronix, NAOV, Reverse Stock Split, Nasdaq Capital Market, Medical Technology, SEC Filing, 8-K, Corporate Action, Stock Split, Share Consolidation, PainShield, UroShield, ENvue Navigation Platform